Latest Financial Results
Q2 2024
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2023
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.
Stock Information
Company Overview
Intensity Therapeutics, Inc. is a late-stage clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anticancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx℠ discovery platform. Our platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Amphiphilic molecules have two distinct components: one part is soluble in water and the other is soluble in fat or oils. When an amphiphilic compound is mixed with therapeutic agents, such as chemotherapies, the agents also become soluble in both fat and water.
Our lead product candidate, INT230-6, consists of two proven anticancer cytotoxic agents, cisplatin and vinblastine, mixed with the amphiphilic molecule (SHAO) — all in one vial. In June 2024, we initiated a Phase 3 clinical trial in metastatic sarcoma, the INVINCIBLE-3 study. Phase three study will test our drug compared to the standard of care in second and third line treatment. We also plan to initiate a Phase 2/3 program testing our drug with and without the standard of care neoadjuvant therapy in women with triple negative breast cancer. Prior to these two late stage studies we completed two studies; the first study was a phase 1/2 dose escalation study in patients with refractory metastatic cancer. The second study was a randomized window of opportunity study that tested our drug in women who, after diagnosis, must wait until the surgery. More information about all our clinical trials may be found on our clinical research page.
IR Contacts
Headquarters
Intensity Therapeutics, Inc.
1 Enterprise Drive
Suite 430
Shelton, CT 06484-4779
T: 203-221-7381
F: 203-557-3023
info@intensitytherapeutics.com
Investor Relations
CORE IR
Justin Kulik
T: 516-222-2560
coreirteam@coreir.com
Transfer Agent
Continental Stock Transfer and Trust
1 State Street
30th Floor
New York, NY 10004